GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)

Hisashi Kawazoe, Vladimir N. Bilim, Andrey V. Ugolkov, Kaori Yuuki, Sei Naito, Akira Nagaoka, Tomoyuki Kato, Yoshihiko Tomita*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science